Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong discusses with Proactive's Andrew Scott the news the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, will proceed to the second dose. She says the cohort review committee agreed the therapy to be safe with no dose-limitiing toxicities and no serious adverse reactions for the first three patients dosed.
Imugene's Leslie Chong details dose escalation for its phase I clinical trial of PD1-Vaxx
